Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nurix Therapeutics (Nasdaq: NRIX), a clinical stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Arthur T. Sands, M.D., Ph.D., president and CEO, will deliver a corporate update on December 3, 2024, at 2:30 p.m. ET in New York City. The presentation will be available via live webcast through the company's website, with the recording accessible for 30 days following the event.
Nurix Therapeutics (Nasdaq: NRIX), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di farmaci a modulazione proteica mirata per il cancro e le malattie infiammatorie, ha annunciato la sua partecipazione alla 36ª Conferenza Sanitaria Annuale di Piper Sandler. Arthur T. Sands, M.D., Ph.D., presidente e CEO, presenterà un aggiornamento aziendale il 3 dicembre 2024, alle 14:30 ET a New York City. La presentazione sarà disponibile tramite webcast dal vivo sul sito web dell'azienda, con la registrazione accessibile per 30 giorni dopo l'evento.
Nurix Therapeutics (Nasdaq: NRIX), una empresa biofarmacéutica en etapa clínica enfocada en desarrollar medicamentos de modulación proteica dirigida para el cáncer y enfermedades inflamatorias, ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. Arthur T. Sands, M.D., Ph.D., presidente y CEO, ofrecerá una actualización corporativa el 3 de diciembre de 2024, a las 2:30 p.m. ET en la ciudad de Nueva York. La presentación estará disponible a través de una transmisión web en vivo a través del sitio web de la empresa, y la grabación estará accesible durante 30 días después del evento.
Nurix Therapeutics (Nasdaq: NRIX)은 암 및 염증 질환을 위한 표적 단백질 조절 약물 개발에 중점을 둔 임상 단계의 생명공학 회사로, Piper Sandler 제36회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다. Arthur T. Sands, M.D., Ph.D.는 2024년 12월 3일 오후 2:30 ET에 뉴욕에서 기업 업데이트를 제공합니다. 이 발표는 회사 웹사이트를 통해 라이브 웹캐스트로 제공되며, 이벤트 후 30일 동안 녹취가 가능합니다.
Nurix Therapeutics (Nasdaq: NRIX), une entreprise biopharmaceutique en phase clinique axée sur le développement de médicaments à modulation protéique ciblée pour le cancer et les maladies inflammatoires, a annoncé sa participation à la 36e Conférence Annuelle de Santé de Piper Sandler. Arthur T. Sands, M.D., Ph.D., président et directeur général, présentera une mise à jour de l'entreprise le 3 décembre 2024 à 14h30 ET à New York City. La présentation sera disponible par webcast en direct sur le site web de l'entreprise, avec un enregistrement accessible pendant 30 jours après l'événement.
Nurix Therapeutics (Nasdaq: NRIX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von zieltäuglichen Proteinmodulationsmedikamenten für Krebs und entzündliche Erkrankungen konzentriert, hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler angekündigt. Arthur T. Sands, M.D., Ph.D., Präsident und CEO, wird am 3. Dezember 2024 um 14:30 Uhr ET in New York City eine Unternehmensaktualisierung präsentieren. Die Präsentation wird über einen Live-Webcast auf der Website des Unternehmens verfügbar sein, und die Aufzeichnung wird 30 Tage nach der Veranstaltung zugänglich sein.
- None.
- None.
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the Piper Sandler 36th Annual Healthcare Conference, at 2:30 p.m. ET on Tuesday, December 3, 2024, in New York City.
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available for 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
When is Nurix Therapeutics (NRIX) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Nurix Therapeutics (NRIX) presentation at the Piper Sandler Conference?
What type of drugs is Nurix Therapeutics (NRIX) developing?
